There are currently 52 active clinical trials seeking participants for Urothelial Carcinoma research studies. The states with the highest number of trials for Urothelial Carcinoma participants are California, New York, Texas and Florida.
Bladder Cancer Screening Trial
Recruiting
There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.
Gender:
All
Ages:
50 years and above
Trial Updated:
07/17/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Bladder Cancer, Urothelial Carcinoma, Hematuria, Smoking Cessation
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Recruiting
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
Recruiting
A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin as switch maintenance therapy for mUC following stable or responding disease on 4-6 cycles of first line platinum-based chemotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: AdventHealth Cancer Institute, Orlando, Florida
Conditions: Metastatic Cancer, Urothelial Carcinoma
A Study of ICP-192 in Patients With Advanced Solid Tumors
Recruiting
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2023
Locations: Arizona Oncology, Tucson, Arizona +15 locations
Conditions: Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma